INS and metabolic syndrome: Along with the discussion above, brain insulin resistance due to metabolic disorders such as diabetes mellitus, metabolic syndrome, and nonalcoholic fatty liver disease are considered to be a prominent component of AD pathology; the maintenance of brain insulin supply should also be a target of AD therapy for individuals with metabolic disorder [34].